Description
Gemcitabine (Gemoxen) 200 Online
Gemoxen (Gemoxen) is used to treat various forms of cancer including pancreatic cancer, non-small cell lung cancer, bladder cancer, soft-tissue sarcoma, metastatic breast cancer, and ovarian cancer.
Gemcitabine Injection in combination with paclitaxel is indicated for the first-line treatment of patients with metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy unless anthracyclines were clinically contraindicated. Gemcitabine is indicated as first-line treatment for patients with locally advanced (nonresectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine Injection is indicated for patients previously treated with fluorouracil.
The recommended dosage of Gemcitabine injection is 1,000 mg/m 2 intravenously over 30 minutes on Days 1 and 8 of each 21-day cycle, in combination with carboplatin AUC 4 administered intravenously on Day 1 after Gemcitabine injection administration. Refer to carboplatin prescribing information for additional information. Gemcitabine injection is a cytotoxic drug. Follow applicable special handling and disposal procedures. 1 Exercise caution and wear gloves when preparing Gemcitabine injection solutions. Immediately wash the skin thoroughly or rinse the mucosa with copious amounts of water if Gemcitabine injection contacts the skin or mucus membranes. Death has occurred in animal studies due to dermal absorption.
In clinical trials evaluating the maximum tolerated dose of Gemcitabine, prolongation of the infusion time beyond 60 minutes or more frequent than weekly dosing resulted in an increased incidence of clinically significant hypotension, severe flu-like symptoms, myelosuppression, and asthenia. The half-life of Gemcitabine is influenced by the length of the infusion [see Clinical Pharmacology.
